I
I-MAB D
D
IMAB
2.31000
USD
0.10
(4.52%)
مفتوح الان
حجم التداول
1,254
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
188,635,399
الأخبار المقالات
العنوان: I/MAB
القطاع: Healthcare
الصناعة: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).